J7172 Injection, marstacimab-hncq, 0.5 mg

Billable / valid for submission HCPCS Release 2026Q3

Short description: Inj marstacim-hncq, 0.5 mg

Version history

Release	Valid from	Valid to	Description	Billable
2026Q3	2026-07-01	current	Injection, marstacimab-hncq, 0.5 mg	yes

J7100 Infusion, dextran 40, 500 ml
J7110 Infusion, dextran 75, 500 ml
J7120 Ringers lactate infusion, up to 1000 cc
J7121 5% dextrose in lactated ringers infusion, up to 1000 cc
J7131 Hypertonic saline solution, 1 ml
J7165 Injection, prothrombin complex concentrate, human-lans, per i.u. of factor ix activity
J7168 Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
J7169 Injection, coagulation factor xa (recombinant), inactivated-zhzo (andexxa), 10 mg
J7170 Injection, emicizumab-kxwh, 0.5 mg
J7171 Injection, adamts13, recombinant-krhn, 10 iu
J7173 Injection, concizumab-mtci, 0.5 mg
J7174 Injection, fitusiran, 0.04 mg
J7175 Injection, factor x, (human), 1 i.u.
J7176 Injection, human fibrinogen - chmt (fesilty), 1 mg
J7177 Injection, human fibrinogen concentrate (fibryga), 1 mg
J7178 Injection, human fibrinogen concentrate, not otherwise specified, 1 mg
J7179 Injection, von willebrand factor (recombinant), (vonvendi), 1 i.u. vwf:rco
J7180 Injection, factor xiii (antihemophilic factor, human), 1 i.u.
J7181 Injection, factor xiii a-subunit, (recombinant), per iu
J7182 Injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu